Virtual Library

Start Your Search

Jian-an Huang



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer (ID 336)

      12:30 - 13:00  |  Author(s): Jian-an Huang

      • Abstract
      • Slides

      Background

      As a novel multitarget receptor tyrosine kinase inhibitor, anlotinib has been demonstrated to be effective in inhibition of tumor angiogenesis and growth. Interestingly, a subset of advanced non-small cell lung cancer (NSCLC) patients who are refractory to EGFR-TKIs are sensitive to anlotinib treatment, the underlying molecular mechanism remained unclear. Herein, we mainly focus on elucidating the regulatory mechanism treated with anlotinib in overcoming acquired resistance to EGFR-TKIs in NSCLC and thus may develop novel therapeutic strategies for anlotinib aiming at improving the prognosis of patients resistant to TKIs.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      High throughput sequencing analysis, western blot analysis, real-time quantitative reverse transcriptase PCR, RNA interference, CCK-8 and flow cytometry were performed on human NSCLC EGFR-resistant cell lines.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Based on high-throughput sequencing analysis, FGFR1 was highly expressed in gefitinib-resistant cell line when compared to HCC827. In line with the data, anlotinib application obviously inhibitied cell viability, proliferation and promoted apoptosis in HCC827GR cell line. Knockdown of FGFR1 can reverse gefitinib resistance. Research into possible mechanisms indicated that anlotinib treatment down-regulated the phosphorylation levels of Erk and Akt.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Anlotinib can overcome acquired resistance to EGFR-TKIs via inhibiting FGFR1 signaling pathway, which provide a mechanism evidence for the treatment of NSCLC patients.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The First Affiliated Hospital of Soochow University.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.